BlackRock Group’s TG Therapeutics TGTX Stock Holding History

BlackRock Group’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$87K	Buy	18,955 +1,176	+7%	+$6.9K	﹤0.01%	2852
2016 Q3	$138K	Buy	17,779 +504	+3%	+$3.24K	﹤0.01%	2744
2016 Q2	$104K	Sell	17,275 -168	-1%	-$1.37K	﹤0.01%	2783
2016 Q1	$149K	Buy	17,443 +10,542	+153%	+$92.2K	﹤0.01%	2651
2015 Q4	$82K	Sell	6,901 -225	-3%	-$2.84K	﹤0.01%	2739
2015 Q3	$72K	Buy	7,126 +1,918	+37%	+$28.6K	﹤0.01%	2781
2015 Q2	$86K	Buy	+5,208	New	+$82.5K	﹤0.01%	2790

Other funds holding TGTX

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock Group's TGTX Position: Q4 2016 in Review

BlackRock Group increased its TG Therapeutics (TGTX) stake by 6.6% in Q4 2016, buying an estimated $6.9K and bringing the position to 18,955 shares worth $87K. The position accounts for ﹤0.01% of the portfolio, ranked #2852.

BlackRock Group first reported a position in TGTX in Q2 2015 and has held it in 7 quarters since. The position peaked at $149K in Q1 2016. 91 funds tracked by Wall St. Rank hold TGTX as of Q4 2016.

BlackRock Group held 18,955 shares of TG Therapeutics worth $87K as of Q4 2016.
BlackRock Group bought 1,176 TG Therapeutics shares in Q4 2016, an estimated $6.9K.
TG Therapeutics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2852 holding.
BlackRock Group first reported a position in TG Therapeutics in Q2 2015 and has held it in 7 quarters since.
BlackRock Group's TG Therapeutics position peaked at $149K in Q1 2016.
91 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.